$17.61
0.17%
Nasdaq, Sep 18, 04:19 pm EDT. Closed.
ISIN
US52490G1022
Symbol
LEGN

Legend Biotech Corp - ADR Target price 2026 - Analyst rating & recommendation

Legend Biotech Corp - ADR Classifications & Recommendation

Buy
74%
Hold
26%

Legend Biotech Corp - ADR Price Target

Target Price $56.10
Price $17.61
Potential
Number of Estimates 18
18 Analysts have issued a price target Legend Biotech Corp - ADR 2027 . The average Legend Biotech Corp - ADR target price is $56.10. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 23 analysts: 17 Analysts recommend Legend Biotech Corp - ADR to buy, 6 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Legend Biotech Corp - ADR stock has an average upside potential 2027 of . Most analysts recommend the Legend Biotech Corp - ADR stock at Purchase.

Sales and Margin forecast 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Revenue Billion $ 1.03 1.46
64.04% 41.90%
EBITDA Margin -10.46% 0.38%
76.72% 103.63%

20 Analysts have issued a sales forecast Legend Biotech Corp - ADR 2026 . The average Legend Biotech Corp - ADR sales estimate is

$1.5b
unlock
. This is
14.83% higher
unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$1.6b 21.91%
unlock
, the lowest is
$1.4b 7.28%
unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2025 $1.0b 64.04%
2026
$1.5b 41.90%
unlock
2027
$1.8b 25.41%
unlock
2028
$2.1b 12.23%
unlock
2029
$2.5b 22.19%
unlock
2030
$2.8b 11.59%
unlock
2031
$3.0b 6.03%
unlock
2032
$3.2b 6.26%
unlock
2033
$3.3b 4.34%
unlock

10 Analysts have issued an Legend Biotech Corp - ADR EBITDA forecast 2026. The average Legend Biotech Corp - ADR EBITDA estimate is

$5.6m
unlock
. This is
156.57% higher
unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$40.2m 509.36%
unlock
, the lowest is
$-40.1m 308.81%
unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2025 $-108m 61.82%
2026
$5.6m 105.16%
unlock
2027
$345m 6,118.56%
unlock
2028
$434m 25.74%
unlock
2029
$752m 73.32%
unlock
2030
$885m 17.70%
unlock
2031
$677m 23.50%
unlock
2032
$728m 7.48%
unlock
2033
$767m 5.42%
unlock

EBITDA Margin

2025 -10.46% 76.72%
2026
0.38% 103.63%
unlock
2027
18.85% 4,860.53%
unlock
2028
21.12% 12.04%
unlock
2029
29.95% 41.81%
unlock
2030
31.59% 5.48%
unlock
2031
22.80% 27.83%
unlock
2032
23.06% 1.14%
unlock
2033
23.30% 1.04%
unlock

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -0.81 -0.01
68.75% 98.77%
P/E negative
EV/Sales 1.86

20 Analysts have issued a Legend Biotech Corp - ADR forecast for earnings per share. The average Legend Biotech Corp - ADR EPS is

$-0.01
unlock
. This is
96.00% higher
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$0.16 164.00%
unlock
, the lowest is
$-0.23 8.00%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-0.81 68.75%
2026
$-0.01 98.77%
unlock
2027
$0.58 5,900.00%
unlock
2028
$0.92 58.62%
unlock
2029
$1.99 116.30%
unlock
2030
$3.36 68.84%
unlock
2031
$3.50 4.17%
unlock
2032
$3.86 10.29%
unlock

P/E ratio

Current -70.44 89.34%
2026
-2,120.97 2,911.03%
unlock
2027
30.15 101.42%
unlock
2028
19.23 36.22%
unlock

Based on analysts' sales estimates for 2026, the Legend Biotech Corp - ADR stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 2.14 69.90%
2026
1.86 12.94%
unlock
2027
1.49 20.26%
unlock
2028
1.32 10.90%
unlock
2029
1.08 18.16%
unlock
2030
0.97 10.38%
unlock
2031
0.92 5.70%
unlock
2032
0.86 5.89%
unlock
2033
0.83 4.16%
unlock

P/S ratio

Current 2.68 65.81%
2026
2.33 12.92%
unlock
2027
1.86 20.26%
unlock
2028
1.66 10.90%
unlock
2029
1.36 18.16%
unlock
2030
1.22 10.39%
unlock
2031
1.15 5.68%
unlock
2032
1.08 5.90%
unlock
2033
1.03 4.16%
unlock

Current Legend Biotech Corp - ADR Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Barclays
Locked
Locked
Locked Sep 11 2026
HC Wainwright & Co.
Locked
Locked
Locked Sep 04 2026
Morgan Stanley
Locked
Locked
Locked Aug 12 2026
Barclays
Locked
Locked
Locked Aug 12 2026
RBC Capital
Locked
Locked
Locked Aug 12 2026
Oppenheimer
Locked
Locked
Locked Aug 12 2026
TD Cowen
Locked
Locked
Locked Aug 12 2026
Analyst Rating Date
Locked
Barclays:
Locked
Locked
Sep 11 2026
Locked
HC Wainwright & Co.:
Locked
Locked
Sep 04 2026
Locked
Morgan Stanley:
Locked
Locked
Aug 12 2026
Locked
Barclays:
Locked
Locked
Aug 12 2026
Locked
RBC Capital:
Locked
Locked
Aug 12 2026
Locked
Oppenheimer:
Locked
Locked
Aug 12 2026
Locked
TD Cowen:
Locked
Locked
Aug 12 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today